Switch theme
Sign up to access all valuation multiples
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
2019
68
LTM Revenue $32.8M
Last FY EBITDA -$241M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NewAmsterdam Pharma Co has a last 12-month revenue (LTM) of $32.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, NewAmsterdam Pharma Co achieved revenue of $45.6M and an EBITDA of -$241M.
NewAmsterdam Pharma Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NewAmsterdam Pharma Co valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $32.8M | XXX | $45.6M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$241M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -530% | XXX | XXX | XXX |
| EBIT | -$212M | XXX | -$176M | XXX | XXX | XXX |
| EBIT Margin | -646% | XXX | -387% | XXX | XXX | XXX |
| Net Profit | -$224M | XXX | -$242M | XXX | XXX | XXX |
| Net Margin | -683% | XXX | -530% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, NewAmsterdam Pharma Co's stock price is $18.
NewAmsterdam Pharma Co has current market cap of $2.0B, and EV of $1.2B.
See NewAmsterdam Pharma Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $2.0B | XXX | XXX | XXX | XXX | $-2.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, NewAmsterdam Pharma Co has market cap of $2.0B and EV of $1.2B.
NewAmsterdam Pharma Co's trades at 27.2x EV/Revenue multiple, and -5.1x EV/EBITDA.
Equity research analysts estimate NewAmsterdam Pharma Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NewAmsterdam Pharma Co has a P/E ratio of -9.1x.
See valuation multiples for NewAmsterdam Pharma Co and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 37.7x | XXX | 27.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -5.1x | XXX | XXX | XXX |
| EV/EBIT | -5.8x | XXX | -7.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.1x | XXX | -8.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -7.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNewAmsterdam Pharma Co's last 12 month revenue growth is -45%
NewAmsterdam Pharma Co's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $3.3M for the same period.
NewAmsterdam Pharma Co's rule of 40 is -1300% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NewAmsterdam Pharma Co's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NewAmsterdam Pharma Co and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -45% | XXX | -41% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -530% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1300% | XXX | -575% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 332% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 487% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NewAmsterdam Pharma Co acquired XXX companies to date.
Last acquisition by NewAmsterdam Pharma Co was XXXXXXXX, XXXXX XXXXX XXXXXX . NewAmsterdam Pharma Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was NewAmsterdam Pharma Co founded? | NewAmsterdam Pharma Co was founded in 2019. |
| Where is NewAmsterdam Pharma Co headquartered? | NewAmsterdam Pharma Co is headquartered in United States of America. |
| How many employees does NewAmsterdam Pharma Co have? | As of today, NewAmsterdam Pharma Co has 68 employees. |
| Who is the CEO of NewAmsterdam Pharma Co? | NewAmsterdam Pharma Co's CEO is Dr. Michael Harvey Davidson, M.D.. |
| Is NewAmsterdam Pharma Co publicy listed? | Yes, NewAmsterdam Pharma Co is a public company listed on NAS. |
| What is the stock symbol of NewAmsterdam Pharma Co? | NewAmsterdam Pharma Co trades under NAMS ticker. |
| When did NewAmsterdam Pharma Co go public? | NewAmsterdam Pharma Co went public in 2022. |
| Who are competitors of NewAmsterdam Pharma Co? | Similar companies to NewAmsterdam Pharma Co include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of NewAmsterdam Pharma Co? | NewAmsterdam Pharma Co's current market cap is $2.0B |
| What is the current revenue of NewAmsterdam Pharma Co? | NewAmsterdam Pharma Co's last 12 months revenue is $32.8M. |
| What is the current revenue growth of NewAmsterdam Pharma Co? | NewAmsterdam Pharma Co revenue growth (NTM/LTM) is -45%. |
| What is the current EV/Revenue multiple of NewAmsterdam Pharma Co? | Current revenue multiple of NewAmsterdam Pharma Co is 37.7x. |
| Is NewAmsterdam Pharma Co profitable? | Yes, NewAmsterdam Pharma Co is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
